Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway

Bausch Health reports modest clinical gains from a 4,251-patient cirrhosis care pilot.

What the company is saying

Bausch Health Companies Inc. (NYSE:BHC, TSX:BHC) and its GI business Salix Pharmaceuticals are highlighting results from a multicenter pilot study testing a standardized clinical pathway for cirrhosis management. The company frames the narrative around improved adherence to evidence-based monitoring and treatment practices, emphasizing measurable gains across five key care metrics. The announcement stresses the pilot’s scale—4,251 patients over six months in five community gastroenterology practices—and positions the pathway as a scalable model for broader adoption. The tone is measured, with claims of feasibility and improved adherence grounded in specific percentage improvements. Principal investigator Peng-Sheng (Brian) Ting, MD, is named to lend clinical credibility. The company also notes that these results are preliminary and will be presented at the American College of Gastroenterology Annual Meeting, with further peer review pending.

What the data suggests

The pilot study involved 4,251 cirrhosis patients and tracked adherence to five clinical process indicators over six months. Office visit adherence improved from 46.9% to 51.1%, a 9.0% relative gain. Laboratory monitoring adherence rose from 61.5% to 63.5%, a 3.2% improvement. Non-selective beta-blocker use for patients with varices increased from 47.2% to 48.8%, a 3.4% relative gain. Hepatic encephalopathy recurrence treatment rates improved from 60.2% to 64.9%, a 7.8% gain. Enrollment in chronic care management programs increased from 11.7% to 12.8%, a 9.4% relative improvement. All improvements are modest but consistent across metrics. The data are internally consistent and reflect process changes, not clinical outcomes or financial impact. No revenue, cost, or commercial adoption figures are disclosed. The findings are described as preliminary and have not yet been peer-reviewed.

Analysis

The announcement presents results from a completed six-month pilot study, with specific, realised improvements in clinical adherence metrics for cirrhosis management. The language is generally proportionate to the evidence, focusing on modest but measurable gains (e.g., 3–9% relative improvements across several indicators). While there are some forward-looking statements about the potential scalability and broader impact of the approach, these are clearly framed as possibilities rather than guaranteed outcomes. No large capital outlay or commercial product claims are made, and all key claims about the pilot's results are supported by disclosed data. The absence of financial or commercial impact metrics limits the investment significance, but the announcement does not overstate its findings or inflate the narrative beyond the evidence presented.

Risk flags

• ●All reported improvements are process metrics, not direct clinical outcomes or financial results, which limits the ability to assess real-world impact or commercial value.
• ●The findings are preliminary and have not yet undergone peer review, so the durability and generalisability of the results are unproven.
• ●Broader adoption of the clinical pathway is only suggested as a possibility, with no evidence yet that these gains can be replicated at scale or outside the pilot context.

Bottom line

Bausch Health’s pilot study demonstrates small but measurable improvements in adherence to cirrhosis care guidelines across a large patient sample. The results are credible within the pilot’s scope, but the announcement provides no evidence of clinical outcome improvements or commercial impact. The company’s narrative is proportionate, avoiding overstatement, but the investment significance is limited by the absence of financial or product adoption data. The next milestone will be peer-reviewed publication and any evidence of broader implementation. For investors, the most important takeaway is that this is an early-stage operational update with no immediate financial implications.

Announcement summary

(NYSE:BHC) (TSX:BHC) Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management. The study, titled 'Development and Implementation of a Cirrhosis Clinical Pathway: Outcomes of a 6-Month Pilot Study,' was conducted over six months across five community gastroenterology practices. The pilot included 4,251 patients with cirrhosis and aimed to reduce variability in care and improve adherence to guideline-recommended management practices. Investigators monitored adherence to five key performance indicators: follow-up office visits, laboratory testing, nonselective beta-blocker use in patients with varices, hepatic encephalopathy treatment, and enrollment in chronic care management programs. Office visit adherence increased from 46.9% at baseline to 51.1%, representing a 9.0% relative improvement. Laboratory monitoring adherence increased from 61.5% to 63.5%, a 3.2% relative improvement. Non-selective beta-blocker treatment rates among patients with varices increased from 47.2% to 48.8%, a 3.4% relative improvement. Medication treatment rates for reducing hepatic encephalopathy recurrence increased from 60.2% to 64.9%, a 7.8% relative improvement. Enrollment in chronic care management/principal care management programs increased from 11.7% to 12.8%, representing a 9.4% relative improvement. The study leveraged the Cardinal Health PPS Analytics platform to identify gaps in care and monitor adherence to predefined clinical pathway benchmarks. Peng-Sheng (Brian) Ting, MD, served as principal investigator of the pilot initiative. The findings will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduate Course, taking place October 9-14, 2026. Investigators concluded that implementation of a standardized cirrhosis clinical pathway, supported by population health analytics, was feasible in community practice and resulted in improved adherence to guideline-based monitoring and treatment recommendations. The approach may serve as a scalable model for improving cirrhosis management in community practice settings. The data presented reflect findings submitted to and accepted for presentation at the ACG Annual Scientific Meeting & Postgraduate Course 2026, and should be considered preliminary until presented and further evaluated in peer-reviewed publications.

Disagree with this article?